Glunektik (Fludeoxyglucose (18f))

Glunektik is indicated for several PET imaging applications where assessment of glucose metabolism provides diagnostic and therapeutic information across multiple medical specialties.

• Oncology: detection, staging, and monitoring of malignant tumors such as lung, breast, colorectal, and lymphoma.
• Neurology: evaluation of epilepsy seizure focus, Alzheimer’s disease, Parkinson’s disease, and cerebral metabolism after injury.
• Cardiology: assessment of myocardial viability, detection of ischemic but viable myocardium, and evaluation of cardiac inflammation.
• Infection and inflammation: localization of bacterial or fungal infections, differentiation from sterile inflammation, and guidance for biopsy.
• Research: quantitative measurement of glucose uptake to assess novel therapies and disease progression in clinical studies.

Adverse reactions to Glunektik are generally related to the radiopharmaceutical nature of the product and the intravenous administration procedure.

Common

• Transient flushing, warmth, or mild erythema at the injection site lasting a few minutes.
• Mild nausea, occasional vomiting, or brief abdominal discomfort occurring shortly after administration.
• Short‑duration headache or light‑headedness that resolves without intervention.
• Temporary metallic or bitter taste in the mouth reported during the first few minutes post‑injection.

Serious

• Allergic reactions ranging from mild urticaria and pruritus to severe anaphylaxis, requiring immediate medical attention.
• Significant radiation‑induced tissue injury, such as skin erythema or ulceration, which is rare when dosing guidelines are followed.
• Severe hypotension, arrhythmias, or cardiovascular collapse that may occur in susceptible patients and necessitate emergency care.

When using Glunektik, clinicians should observe specific precautions to ensure patient safety and optimal image quality.

• Verify patient identity and confirm indication for PET imaging before administration.
• Assess renal function, as impaired clearance may affect radiotracer distribution.
• Ensure adequate hydration and encourage fluid intake after injection to promote renal excretion.
• Review history of allergic reactions to radiopharmaceuticals or iodine‑containing compounds.
• Observe patients for at least 15 minutes post‑injection for any immediate adverse events.
• Pregnant or breastfeeding women should only receive Glunektik if the diagnostic benefit outweighs potential fetal or neonatal radiation exposure.
• Coordinate with the PET imaging facility to schedule scanning within the appropriate time window after injection to capture optimal tracer uptake.

Glunektik may interact with certain medications or conditions that influence glucose metabolism, radiation exposure, or hemodynamic stability.

Avoid

• Avoid concurrent administration of high‑dose glucose or dextrose solutions immediately before or after the radiotracer, as they can competitively inhibit tracer uptake.
• Avoid use in patients receiving other radiopharmaceuticals within a short interval, which could increase cumulative radiation dose.

Use with caution

• Use with caution in patients on insulin or oral hypoglycemic agents; blood glucose levels should be controlled to avoid false‑negative PET results.
• Use with caution in individuals with severe renal impairment, as reduced clearance may alter biodistribution.
• Use with caution when combined with iodinated contrast agents, which may affect image interpretation.